source
- Argenx acquires Unnatural Products for up to $1.15 billion to boost oral peptide platformArgenx announced it will buy biotech Unnatural Products, paying $550 million upfront with the total deal value potentially reaching $1.15 billion through development and regulatory milestones. The…
- Valneva's Shigella vaccine cuts infection rates in phase 2 trialValneva reported that its Shigella vaccine reduced the number of intestinal infections in a phase 2 controlled human infection model study conducted in the United States. The trial enrolled 120 he…